Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$23.90+1.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Arcutis Biotherapeutics aims to grow revenue to about $487 million in 2026. Its dermatology drug ZORYVE is driving sales growth. The company is working to improve its operating income after a recent loss. Positive earnings beats show some progress.
The company is still loss-making with operating income down to -$9.1 million in Q1 2026. Revenue growth must accelerate sharply to meet guidance from $105.4 million in Q1 to nearly $487 million full year. Analyst estimates have been revised down recently.
The market has mixed views with no clear consensus on revenue growth or fair value. Recent analyst EPS estimates have declined, reflecting caution. Our view is that the company must deliver strong revenue growth and margin improvement to justify optimism.
Breaks if: Operating income remains negative or worsens through FY26
Breaks if: Revenue falls below $480M in FY26
ZORYVE sales decline or stall in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment focused on the healthcare sector. The current thesis is intact, supported by strong revenue growth and management's stable execution, despite being loss-making.
The market seems to price in a fragile valuation, as ARQT is considered expensive compared to its peers. There is an expectations gap, suggesting that investors may not fully believe in the company's growth trajectory.
Fundamentals are likely to show continued strong revenue growth, as management is on track to meet its 2026 revenue guidance. However, the elevated risk from potential industry downturns and recent earnings misses among peers could impact performance.
The thesis hinges on ARQT's ability to maintain its growth momentum and successfully expand its product pipeline. Additionally, the performance of sector bellwethers and overall market conditions will play a critical role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Valuation rose by 20.1 points (from 47.1 to 67.2).
Signal changed from 'mild_favorable' to 'favorable'.
Yes, our read has weakened. The latest earnings beat is a positive factor. However, a sharp drop in the stock price may indicate a repricing of the thesis. This price movement suggests that the market is reassessing the reasons to own the stock.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, ARQT's performance and management execution will be key over the next 1-3 years. Not investment advice.